Parameter | ≤ 10% stromal TILs | > 10 to ≤ 40% stromal TILs | > 40 to ≤ 90% stromal TILs | P valuea |
---|---|---|---|---|
Tumor with no/minimal immune cells (n = 92, 73%) | Tumor with intermediate/heterogeneous infiltrate (n = 25, 20%) | Tumor with high immune infiltrate (n = 9, 7%) | ||
Age, years | ||||
Median (range) | 52 (29–82) | 56 (38–75) | 61 (47–77) | |
Mean ± SD | 52.8 ± 11.6 | 55.8 ± 11.1 | 61.2 ± 8.7 | |
T | ||||
T1 | 37 (71) | 10 (19) | 5 (10) | 0.821 |
T2 | 47 (65) | 15 (23) | 3 (5) | 0.744 |
T3 | 8 (89) | 0 | 1 (11) | 0.307 |
N | ||||
N0 | 44 (69) | 16 (25) | 4 (6) | 0.726 |
N1 | 32 (74) | 8 (19) | 3 (7) | 1 |
N2 | 9 (82) | 1 (9) | 1 (9) | 0.748 |
N3 | 6 (86) | 0 | 1 (14) | 0.290 |
Nxb | 1 (100) | 0 | 0 | |
M | ||||
M0 | 79 (75) | 20 (19) | 6 (6) | 0.919 |
Mxc | 13 (62) | 5 (24) | 3 (14) | 0.361 |
Stage | ||||
I | 22 (73) | 6 (20) | 2 (7) | 1 |
II | 53 (70) | 18 (24) | 5 (7) | 0.826 |
III | 17 (85) | 1 (5) | 2 (10) | 0.204 |
Histological type | ||||
Invasive ductal carcinoma | 80 (75) | 19 (18) | 7 (7) | 0.921 |
Invasive lobular carcinoma | 10 (59) | 5 (29) | 2 (12) | 0.371 |
Other | 2 (67) | 1 (33) | 0 | |
Estrogen receptor status | ||||
Positive | 79 (75) | 19 (18) | 7 (7) | 0.947 |
Negative | 13 (62) | 6 (29) | 2 (10) | 0.560 |
Progesterone receptor status | ||||
Positive | 71 (76) | 16 (17) | 6 (6) | 0.888 |
Negative | 21 (64) | 9 (27) | 3 (9) | 0.515 |
Human epidermal growth factor receptor 2 status | ||||
Positive | 14 (61) | 6 (26) | 3 (13) | 0.384 |
Negative | 76 (76) | 19 (19) | 5 (5) | 0.790 |
Equivocal | 2 (67) | 0 | 1 (33) | |
IHC subtype | ||||
HR+/HER2− | 68 (78) | 14 (16) | 5 (6) | 0.824 |
HER2+ | 14 (61) | 6 (26) | 3 (13) | 0.571 |
ER−/PR−/HER2− | 10 (63) | 5 (31) | 1 (6) | 0.592 |
PAM50 intrinsic subtype | ||||
Luminal A | 53 (75) | 13 (18) | 5 (7) | 0.966 |
Luminal B | 22 (79) | 4 (14) | 2 (7) | 0.875 |
HER2 | 4 (50) | 3 (38) | 1 (12) | 0.219 |
Basal | 10 (63) | 5 (31) | 1 (6) | 0.536 |
Normal | 3 (100) | 0 | 0 |